Neurotech International Ltd. (AU:NTI) has released an update.
Neurotech International Ltd. has reported significant improvements in anxiety and depression among children with Autism Spectrum Disorder (ASD) in their Phase II/III clinical trial for the drug NTI164. The trial revealed a clinically meaningful and statistically significant reduction in symptoms according to the Anxiety, Depression and Mood Scale (ADAMS), even for children already on existing medications. These results reinforce the potential of NTI164 as a treatment option where safe and effective therapies for ASD are in high demand.
For further insights into AU:NTI stock, check out TipRanks’ Stock Analysis page.
